stockrow
Friday 6 November 2026
Export KMTS’s income statement to Excel — free account
Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025.
- Revenue
- +59.9%
- EPS
- −50.0%
- Free cash flow
- −17.8%
- Total debt
- +74.7%
Quarter to July 2026, against a year earlier
27.97
2.53
−8.30%
Follow KMTS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jul ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 28 | 60 | 95 | 107 | +84.9% | 141 | 196 | 272 | +41.9% | |
| Gross margin, % | — | — | — | — | — | — | — | 1.30 | 40.47 | 51.37 | 53.89 | +50.1 pt | ||||||
| EBT | — | — | — | — | — | — | — | (94) | (114) | (131) | (150) | +18.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (338.30) | (190.05) | (138.05) | (140.14) | +200.3 pt | ||||||
| Net income | — | — | — | — | — | — | — | (94) | (114) | (132) | (150) | +18.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 1.40 | 2.43 | 1.76 | 1.82 | +12.0% | |||||
| Earnings | — | — | — | — | — | — | — | (5.07) | (5.13) | (2.43) | (2.67) | (30.8%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (3.63) | (3.16) | (1.51) | (1.50) | (35.6%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.61) | (0.95) | (0.65) | (0.60) | +2.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (4.25) | (4.10) | (2.16) | (2.10) | (28.7%) | ||||||
| Book value | — | — | — | — | — | — | — | (1.62) | 8.36 | 4.79 | 3.80 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 20 | 25 | 54 | 55 | +65.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 9.89 | 11.80 | 15.35 | 7.2 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 2.88 | 4.32 | 7.37 | 2.4 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 6.60 | 10.19 | 14.16 | 5.6 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (3.04) | (3.91) | (8.29) | (12.28) | (5.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (72) | (78) | (82) | (88) | +6.4% | |||||
| Capex | — | — | — | — | — | — | — | (12) | (23) | (35) | (35) | +69.7% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (84) | (101) | (117) | (123) | +17.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (18) | 217 | 172 | 178 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | 34 | (196) | (154) | (126) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (32) | 205 | 260 | 222 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (73.83) | (40.24) | (48.85) | (40.2) pt | |||||
| ROIC | — | — | — | — | — | — | — | (2,631.90) | (746.28) | (79.54) | (93.49) | +2,552.4 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 6,352.81 | (56.60) | (73.74) | (56.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 300 | 330 | 443 | — | +21.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.09 | 0.18 | 0.21 | — | +52.2% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 25 Oct 2026
Kestra Medical Technologies, Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PLSE Pulse Biosciences, Inc | $3.9B | — (loss-making) | — (loss-making) | +359.30% (above 0%: growing) | n/m | −1,180.54% (below 0%: shrinking) | 51.65% | (6,149.87%) | Compare |
| STVN Stevanato Group S.p.A. | $3.6B | 22.4× | 30.2× | +5.91% (above 0%: growing) | +17.53% (above 0%: growing) | +4,089.92% (above 0%: growing) | 29.12% | 18.51% | Compare |
| WRBY Warby Parker Inc. | $3.2B | 434× | 208× | +10.40% (above 0%: growing) | −20.00% (below 0%: shrinking) | −30.28% (below 0%: shrinking) | 54.41% | 1.45% | Compare |
| ATRC AtriCure, Inc. | $3.1B | 199× | 573× | +15.03% (above 0%: growing) | n/m | −0.73% (below 0%: shrinking) | 77.27% | 2.82% | Compare |
| XRAY DENTSPLY SIRONA Inc. | $2.0B | — (loss-making) | 24.5× | −7.52% (below 0%: shrinking) | n/m | −17.95% (below 0%: shrinking) | 52.99% | 4.43% | Compare |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 29.7× | 28.2× | +11.34% (above 0%: growing) | −14.29% (below 0%: shrinking) | −25.78% (below 0%: shrinking) | 71.66% | 26.03% | Compare |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | — (loss-making) | — (loss-making) | +59.88% (above 0%: growing) | n/m | −17.75% (below 0%: shrinking) | 56.50% | (121.59%) | |
| AZTA Azenta, Inc. | $1.6B | — (loss-making) | — (loss-making) | +12.04% (above 0%: growing) | n/m | −134.69% (below 0%: shrinking) | 44.89% | (2.59%) | Compare |
| STAA STAAR Surgical Company | $1.3B | — (loss-making) | 84.4× | −11.95% (below 0%: shrinking) | −38.89% (below 0%: shrinking) | +1,378.70% (above 0%: growing) | 70.90% | 6.54% | Compare |
| Median of peers | $2.6B | 114× | 57.3× | +10.87% | −17.14% | −21.86% | 53.70% | 3.63% |
Pay and ownership Proxy statement filed 28 July 2026
Ownership
Directors and executive officers, together
5.30%
Affiliate of Bain Capital
43.00%
T. Rowe Price Associates, Inc.
10.20%
FMR LLC
8.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement